Inlexisertib

DRUG2 trials

Sponsors

Deciphera Pharmaceuticals, LLC

Conditions

Advanced Solid TumorGISTMetastatic Solid TumorNon-Small Cell Lung Cancer

Phase 1

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

TerminatedNCT04892017

Deciphera Pharmaceuticals, LLCAdvanced Solid Tumor, Metastatic Solid Tumor, Non-Small Cell Lung Cancer

Start: 2021-06-15End: 2026-03-30Updated: 2026-04-08

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

RecruitingNCT05957367

Deciphera Pharmaceuticals, LLCGIST

Start: 2023-09-28End: 2029-03-01Target: 94Updated: 2026-07-23

Related Papers

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.

2025-01-269 citations

DCC-3116 in combination with ripretinib for patients with advanced gastrointestinal stromal tumor: A phase 1/2 study.

Journal of Clinical Oncology2024-06-011 citations

A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced <i>KRAS</i>-Mutant Non-Small Cell Lung Cancer

The Oncologist2023-04-2618 citations

Abstract 1377: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with encorafenib and cetuximab in BRAF V600E mutant colorectal cancer models

Cancer Research2023-04-042 citations

Abstract 4872: DCC-3116, a first-in-class selective ULK1/2 inhibitor of autophagy, in combination with the KIT inhibitor ripretinib induces complete regressions in GIST preclinical models

Cancer Research2023-04-042 citations

Abstract 3600: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with the KRASG12C inhibitor sotorasib resulting in tumor regression in KRAS mutant NSCLC xenograft models

Cancer Research2022-06-159 citations

A phase 1/2 study of DCC-3116 as a single agent and in combination with trametinib in patients with advanced or metastatic solid tumors with RAS or RAF mutations.

Journal of Clinical Oncology2022-06-0111 citations

Abstract P084: DCC-3116, a first-in-class selective inhibitor of ULK1/2 kinases and autophagy, synergizes with EGFR inhibitors osimertinib and afatinib in NSCLC preclinical models

Molecular Cancer Therapeutics2021-12-015 citations